09/26/23 7:27 AMNasdaq : CRDL conferencesCardiol Therapeutics to Present at Cantor Fitzgerald 2023 Global Healthcare ConferenceCardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (" Cardiol" or the " Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatmentRHEA-AIneutral
09/19/23 7:27 AMNasdaq : CRDL clinical trialCardiol Therapeutics Announces All Collaborating Clinical Research Centers Now Initiated and Eligible to Enroll Patients in ARCHER, a Phase II Trial of CardiolRx(TM) for the Treatment of Acute MyocarditisCardiolRHEA-AIneutral
08/09/23 7:27 AMNasdaq : CRDL conferencesCardiol Therapeutics to Present at Canaccord Genuity 43rd Annual Growth ConferenceCardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (" Cardiol" or the " Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment ofRHEA-AIneutral
08/08/23 7:27 AMNasdaq : CRDL Cardiol Therapeutics Regains Compliance with all Applicable Listing Standards of The Nasdaq Capital MarketCardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (" Cardiol" or the " Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment ofRHEA-AIneutral
06/29/23 10:19 AMNasdaq : CRDL Cardiol Therapeutics Reports Results of 2023 Annual General MeetingCardiol Therapeutics Inc. ( NASDAQ: CRDL) ( TSX: CRDL) (" Cardiol" or the " Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment ofRHEA-AIneutral
06/27/23 7:27 AMNasdaq : CRDL conferencesCardiol Therapeutics to Webcast Virtual Annual General Meeting on June 28th at 4:30 p.m. EDTCardiol Therapeutics Inc. ( NASDAQ: CRDL) ( TSX: CRDL) (" Cardiol" or the " Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment ofRHEA-AIneutral
